IFN-lambda 2/IL-28A, Human (P.pastoris, His)

IFN-lambda 2/IL-28A, Human (P.pastoris, His)

• UNSPSC Description: IFN-lambda 2 (IL-28A) is a member of the Type-III interferon family. IFN-lambda 2 has antiviral antitumour and immunomodulatory activities[1]. IFN-lambda 2 signals through a heterodimeric receptor complex comprising IFNLR1 and IL-10RB. When binding to the receptor complex, Jak1 and Tyk2 will be activated, and leads to tyrosine phosphorylation of the IFN-λR1 and activation of STAT1 and STAT2. Activated STAT1 and STAT2 together with IRF-9 form a trimeric transcription factor complex (ISGF3). The formed ISGF3 then translocate to the nucleus and promotes the production of IFN-stimulated genes (ISGs)[2]. IFN-lambda 2/IL-28A Protein, Human (P.pastoris, His) is a recombinant human IFN-lambda 2 (V26-V200) with C-terminal His tag, which is expressed in P.pastoris.
• Type: Recombinant Proteins
• Assay Protocol: https://www.medchemexpress.com/cytokines/ifn-lambda-2-il-28a-protein-human-p-pastoris-his.html
• Molecular Weight: Approximately 21.1 kDa.
• References & Citations: [1]Lopušná K, et al. Interferons lambda, new cytokines with antiviral activity. Acta Virol. 2013;57(2):171-9.|[2]Donnelly RP, et al. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res. 2010 Aug;30(8):555-64.|[3]Witte K, et al. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010 Aug;21(4):237-51. |[4]Yan B, et al. Interleukin-28B dampens airway inflammation through up-regulation of natural killer cell-derived IFN-γ. Sci Rep. 2017 Jun 15;7(1):3556. |[5]Luo Q, et al. Interleukin 28 is a potential therapeutic target for sepsis. Clin Immunol. 2019 Aug;205:29-34.|[6]Liangzi Li, et al. Interleukin-28A maintains the intestinal epithelial barrier function through regulation of claudin-1.
• Shipping Conditions: Room temperature